New eye drop TFC-003 aims to lower glaucoma pressure
NCT ID NCT07662759
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tests TFC-003, a new eye drop, in 188 adults with primary open-angle glaucoma or ocular hypertension. Participants use the drops twice daily for up to 24 weeks. The main goal is to see if TFC-003 lowers eye pressure better than an active control. The study is currently recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TFC-003 eye drops
What this could lead to
If successful, this could provide a new treatment option to help control eye pressure in people with glaucoma or ocular hypertension.
What could go wrong
This is a phase 3 trial, but results may not confirm superiority over existing treatments. Side effects or lack of long-term benefit are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OCULAR HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Kukje Pharma
RECRUITINGSeongnam, South Korea
Contact